TABLE 6B - NEW PROCEDURE CODES
Procedure Code	Description	O.R.	MDC	MS-DRG
02VL0CZ	Restriction of Left Ventricle with Extraluminal Device, Open Approach	Y	05	270, 271, 272
""			21	907, 908, 909
""				981, 982, 983
02VL0DZ	Restriction of Left Ventricle with Intraluminal Device, Open Approach	Y	05	270, 271, 272
""			21	907, 908, 909
""				981, 982, 983
02VL0ZZ	Restriction of Left Ventricle, Open Approach	Y	05	270, 271, 272
""			21	907, 908, 909
""				981, 982, 983
02VL3CZ	Restriction of Left Ventricle with Extraluminal Device, Percutaneous Approach	Y	05	273, 274
""			21	907, 908, 909
""				981, 982, 983
02VL3DZ	Restriction of Left Ventricle with Intraluminal Device, Percutaneous Approach	Y	05	270, 271, 272
""			21	907, 908, 909
""				981, 982, 983
02VL3ZZ	Restriction of Left Ventricle, Percutaneous Approach	Y	05	273, 274
""			21	907, 908, 909
""				981, 982, 983
02VL4CZ	Restriction of Left Ventricle with Extraluminal Device, Percutaneous Endoscopic Approach	Y	05	270, 271, 272
""			21	907, 908, 909
""				981, 982, 983
02VL4DZ	Restriction of Left Ventricle with Intraluminal Device, Percutaneous Endoscopic Approach	Y	05	270, 271, 272
""			21	907, 908, 909
""				981, 982, 983
02VL4ZZ	Restriction of Left Ventricle, Percutaneous Endoscopic Approach	Y	05	270, 271, 272
""			21	907, 908, 909
""				981, 982, 983
03173ZF	Bypass Right Brachial Artery to Lower Arm Vein, Percutaneous Approach	Y	05	264
""			10	628, 629, 630
""			11	673, 674, 675
""			21	907, 908, 909
""			24	957, 958, 959
""				981, 982, 983
03183ZF	Bypass Left Brachial Artery to Lower Arm Vein, Percutaneous Approach	Y	05	264
""			10	628, 629, 630
""			11	673, 674, 675
""			21	907, 908, 909
""			24	957, 958, 959
""				981, 982, 983
06LY7CC	Occlusion of Hemorrhoidal Plexus with Extraluminal Device, Via Natural or Artificial Opening	Y	06	347, 348, 349
""				987, 988, 989
06LY7CZ	Occlusion of Lower Vein with Extraluminal Device, Via Natural or Artificial Opening	Y	05	263
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
06LY7DC	Occlusion of Hemorrhoidal Plexus with Intraluminal Device, Via Natural or Artificial Opening	Y	06	347, 348, 349
""				987, 988, 989
06LY7DZ	Occlusion of Lower Vein with Intraluminal Device, Via Natural or Artificial Opening	Y	05	263
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
06LY7ZC	Occlusion of Hemorrhoidal Plexus, Via Natural or Artificial Opening	Y	06	347, 348, 349
""				987, 988, 989
06LY7ZZ	Occlusion of Lower Vein, Via Natural or Artificial Opening	Y	05	263
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
06LY8CC	Occlusion of Hemorrhoidal Plexus with Extraluminal Device, Via Natural or Artificial Opening Endoscopic	Y	06	347, 348, 349
""				987, 988, 989
06LY8CZ	Occlusion of Lower Vein with Extraluminal Device, Via Natural or Artificial Opening Endoscopic	Y	05	263
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
06LY8DC	Occlusion of Hemorrhoidal Plexus with Intraluminal Device, Via Natural or Artificial Opening Endoscopic	Y	06	347, 348, 349
""				987, 988, 989
06LY8DZ	Occlusion of Lower Vein with Intraluminal Device, Via Natural or Artificial Opening Endoscopic	Y	05	263
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
06LY8ZC	Occlusion of Hemorrhoidal Plexus, Via Natural or Artificial Opening Endoscopic	Y	06	347, 348, 349
""				987, 988, 989
06LY8ZZ	Occlusion of Lower Vein, Via Natural or Artificial Opening Endoscopic	Y	05	263
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
07DT0ZX	Extraction of Bone Marrow, Open Approach, Diagnostic	N		
07DT0ZZ	Extraction of Bone Marrow, Open Approach	N		
07DT3ZX	Extraction of Bone Marrow, Percutaneous Approach, Diagnostic	N		
07DT3ZZ	Extraction of Bone Marrow, Percutaneous Approach	N		
0F800ZZ	Division of Liver, Open Approach	Y	07	405, 406, 407
""			21	907, 908, 909
""			24	957, 958, 959
""				981, 982, 983
0F803ZZ	Division of Liver, Percutaneous Approach	N		
0F804ZZ	Division of Liver, Percutaneous Endoscopic Approach	Y	07	405, 406, 407
""			21	907, 908, 909
""			24	957, 958, 959
""				981, 982, 983
0F810ZZ	Division of Right Lobe Liver, Open Approach	Y	07	405, 406, 407
""			21	907, 908, 909
""			24	957, 958, 959
""				981, 982, 983
0F813ZZ	Division of Right Lobe Liver, Percutaneous Approach	N		
0F814ZZ	Division of Right Lobe Liver, Percutaneous Endoscopic Approach	Y	07	405, 406, 407
""			21	907, 908, 909
""			24	957, 958, 959
""				981, 982, 983
0F820ZZ	Division of Left Lobe Liver, Open Approach	Y	07	405, 406, 407
""			21	907, 908, 909
""			24	957, 958, 959
""				981, 982, 983
0F823ZZ	Division of Left Lobe Liver, Percutaneous Approach	N		
0F824ZZ	Division of Left Lobe Liver, Percutaneous Endoscopic Approach	Y	07	405, 406, 407
""			21	907, 908, 909
""			24	957, 958, 959
""				981, 982, 983
0K847ZZ	Division of Tongue, Palate, Pharynx Muscle, Via Natural or Artificial Opening	Y	03	143, 144, 145
""			06	326, 327, 328
""				987, 988, 989
0K848ZZ	Division of Tongue, Palate, Pharynx Muscle, Via Natural or Artificial Opening Endoscopic	Y	03	143, 144, 145
""			06	326, 327, 328
""				987, 988, 989
0NH003Z	Insertion of Infusion Device into Skull, Open Approach	Y	01	023, 024, 025, 026, 027
""			21	907, 908, 909
""			24	955
""				981, 982, 983
0NH033Z	Insertion of Infusion Device into Skull, Percutaneous Approach	Y	01	023, 024, 025, 026, 027
""			21	907, 908, 909
""			24	955
""				981, 982, 983
0NH043Z	Insertion of Infusion Device into Skull, Percutaneous Endoscopic Approach	Y	01	023, 024, 025, 026, 027
""			21	907, 908, 909
""			24	955
""				981, 982, 983
0PS403Z	Reposition Thoracic Vertebra with Spinal Stabilization Device, Vertebral Body Tether, Open Approach	Y	01	028, 029, 030
""			08	518, 519, 520
""			17	820, 821, 822, 826, 827, 828
""			21	907, 908, 909
""			24	957, 958, 959
""				981, 982, 983
0PS443Z	Reposition Thoracic Vertebra with Spinal Stabilization Device, Vertebral Body Tether, Percutaneous Endoscopic Approach	Y	01	028, 029, 030
""			08	518, 519, 520
""			17	820, 821, 822, 826, 827, 828
""			21	907, 908, 909
""			24	957, 958, 959
""				981, 982, 983
0QBN0Z2	Excision of Right Metatarsal, Sesamoid Bone(s) 1st Toe, Open Approach	Y	08	503, 504, 505
""			10	628, 629, 630
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0QBN3Z2	Excision of Right Metatarsal, Sesamoid Bone(s) 1st Toe, Percutaneous Approach	Y	08	503, 504, 505
""			10	628, 629, 630
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0QBN4Z2	Excision of Right Metatarsal, Sesamoid Bone(s) 1st Toe, Percutaneous Endoscopic Approach	Y	08	503, 504, 505
""			10	628, 629, 630
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0QBP0Z2	Excision of Left Metatarsal, Sesamoid Bone(s) 1st Toe, Open Approach	Y	08	503, 504, 505
""			10	628, 629, 630
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0QBP3Z2	Excision of Left Metatarsal, Sesamoid Bone(s) 1st Toe, Percutaneous Approach	Y	08	503, 504, 505
""			10	628, 629, 630
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0QBP4Z2	Excision of Left Metatarsal, Sesamoid Bone(s) 1st Toe, Percutaneous Endoscopic Approach	Y	08	503, 504, 505
""			10	628, 629, 630
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0QS003Z	Reposition Lumbar Vertebra with Spinal Stabilization Device, Vertebral Body Tether, Open Approach	Y	01	028, 029, 030
""			08	518, 519, 520
""			17	820, 821, 822, 826, 827, 828
""			21	907, 908, 909
""			24	957, 958, 959
""				981, 982, 983
0QS043Z	Reposition Lumbar Vertebra with Spinal Stabilization Device, Vertebral Body Tether, Percutaneous Endoscopic Approach	Y	01	028, 029, 030
""			08	518, 519, 520
""			17	820, 821, 822, 826, 827, 828
""			21	907, 908, 909
""			24	957, 958, 959
""				981, 982, 983
0RPJ0J6	Removal of Synthetic Substitute from Right Shoulder Joint, Humeral Surface, Open Approach	Y	08	495, 496, 497
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0RPJ0J7	Removal of Synthetic Substitute from Right Shoulder Joint, Glenoid Surface, Open Approach	Y	08	495, 496, 497
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0RPJ3J6	Removal of Synthetic Substitute from Right Shoulder Joint, Humeral Surface, Percutaneous Approach	Y	08	495, 496, 497
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0RPJ3J7	Removal of Synthetic Substitute from Right Shoulder Joint, Glenoid Surface, Percutaneous Approach	Y	08	495, 496, 497
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0RPJ4J6	Removal of Synthetic Substitute from Right Shoulder Joint, Humeral Surface, Percutaneous Endoscopic Approach	Y	08	495, 496, 497
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0RPJ4J7	Removal of Synthetic Substitute from Right Shoulder Joint, Glenoid Surface, Percutaneous Endoscopic Approach	Y	08	495, 496, 497
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0RPK0J6	Removal of Synthetic Substitute from Left Shoulder Joint, Humeral Surface, Open Approach	Y	08	495, 496, 497
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0RPK0J7	Removal of Synthetic Substitute from Left Shoulder Joint, Glenoid Surface, Open Approach	Y	08	495, 496, 497
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0RPK3J6	Removal of Synthetic Substitute from Left Shoulder Joint, Humeral Surface, Percutaneous Approach	Y	08	495, 496, 497
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0RPK3J7	Removal of Synthetic Substitute from Left Shoulder Joint, Glenoid Surface, Percutaneous Approach	Y	08	495, 496, 497
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0RPK4J6	Removal of Synthetic Substitute from Left Shoulder Joint, Humeral Surface, Percutaneous Endoscopic Approach	Y	08	495, 496, 497
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0RPK4J7	Removal of Synthetic Substitute from Left Shoulder Joint, Glenoid Surface, Percutaneous Endoscopic Approach	Y	08	495, 496, 497
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0RWJ0J6	Revision of Synthetic Substitute in Right Shoulder Joint, Humeral Surface, Open Approach	Y	08	515, 516, 517
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0RWJ0J7	Revision of Synthetic Substitute in Right Shoulder Joint, Glenoid Surface, Open Approach	Y	08	515, 516, 517
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0RWJ3J6	Revision of Synthetic Substitute in Right Shoulder Joint, Humeral Surface, Percutaneous Approach	Y	08	515, 516, 517
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0RWJ3J7	Revision of Synthetic Substitute in Right Shoulder Joint, Glenoid Surface, Percutaneous Approach	Y	08	515, 516, 517
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0RWJ4J6	Revision of Synthetic Substitute in Right Shoulder Joint, Humeral Surface, Percutaneous Endoscopic Approach	Y	08	515, 516, 517
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0RWJ4J7	Revision of Synthetic Substitute in Right Shoulder Joint, Glenoid Surface, Percutaneous Endoscopic Approach	Y	08	515, 516, 517
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0RWJXJ6	Revision of Synthetic Substitute in Right Shoulder Joint, Humeral Surface, External Approach	N		
0RWJXJ7	Revision of Synthetic Substitute in Right Shoulder Joint, Glenoid Surface, External Approach	N		
0RWK0J6	Revision of Synthetic Substitute in Left Shoulder Joint, Humeral Surface, Open Approach	Y	08	515, 516, 517
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0RWK0J7	Revision of Synthetic Substitute in Left Shoulder Joint, Glenoid Surface, Open Approach	Y	08	515, 516, 517
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0RWK3J6	Revision of Synthetic Substitute in Left Shoulder Joint, Humeral Surface, Percutaneous Approach	Y	08	515, 516, 517
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0RWK3J7	Revision of Synthetic Substitute in Left Shoulder Joint, Glenoid Surface, Percutaneous Approach	Y	08	515, 516, 517
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0RWK4J6	Revision of Synthetic Substitute in Left Shoulder Joint, Humeral Surface, Percutaneous Endoscopic Approach	Y	08	515, 516, 517
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0RWK4J7	Revision of Synthetic Substitute in Left Shoulder Joint, Glenoid Surface, Percutaneous Endoscopic Approach	Y	08	515, 516, 517
""			21	907, 908, 909
""			24	957, 958, 959
""				987, 988, 989
0RWKXJ6	Revision of Synthetic Substitute in Left Shoulder Joint, Humeral Surface, External Approach	N		
0RWKXJ7	Revision of Synthetic Substitute in Left Shoulder Joint, Glenoid Surface, External Approach	N		
5A1221J	Performance of Cardiac Output, Continuous, Automated	N		
BF150ZZ	Fluoroscopy of Liver using High Osmolar Contrast	N		
BF151ZZ	Fluoroscopy of Liver using Low Osmolar Contrast	N		
BF15YZZ	Fluoroscopy of Liver using Other Contrast	N		
BF15ZZA	Fluoroscopy of Liver, Guidance	N		
X2V73Q7	Restriction of Coronary Sinus with Reduction Device, Percutaneous Approach, New Technology Group 7	Y	05	228, 229
""				981, 982, 983
XW013H6	Introduction of Other New Technology Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6	N(1)
XW013K6	Introduction of Leronlimab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6	N(1)
XW013S6	Introduction of COVID-19 Vaccine Dose 1 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6	N(1)
XW013T6	Introduction of COVID-19 Vaccine Dose 2 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6	N(1)
XW013U6	Introduction of COVID-19 Vaccine into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6	N(1)
XW023S6	Introduction of COVID-19 Vaccine Dose 1 into Muscle, Percutaneous Approach, New Technology Group 6	N(1)	
XW023T6	Introduction of COVID-19 Vaccine Dose 2 into Muscle, Percutaneous Approach, New Technology Group 6	N(1)
XW023U6	Introduction of COVID-19 Vaccine into Muscle, Percutaneous Approach, New Technology Group 6	N(1)
XW03357	Introduction of Narsoplimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 7	N		
XW03367	Introduction of Terlipressin into Peripheral Vein, Percutaneous Approach, New Technology Group 7	N		
XW033C7	Introduction of Autologous Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7	N**	PRE	018
XW033E6	Introduction of Etesevimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6	N(1)
XW033F6	Introduction of Bamlanivimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6	N(1)
XW033G6	Introduction of REGN-COV2 Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6	N(1)
XW033G7	Introduction of Allogeneic Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7	N**	PRE	018
XW033H6	Introduction of Other New Technology Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6	N(1)
XW033H7	Introduction of Axicabtagene Ciloleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7	N**	PRE	018
XW033J7	Introduction of Tisagenlecleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7	N**	PRE	018
XW033K7	Introduction of Idecabtagene Vicleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7	N**	PRE	018
XW033L6	Introduction of CD24Fc Immunomodulator into Peripheral Vein, Percutaneous Approach, New Technology Group 6	N(1)
XW033L7	Introduction of Lifileucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7	N**	PRE	018
XW033M7	Introduction of Brexucabtagene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7	N**	PRE	018
XW033N7	Introduction of Lisocabtagene Maraleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7	N**	PRE	018
XW04357	Introduction of Narsoplimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 7	N		
XW04367	Introduction of Terlipressin into Central Vein, Percutaneous Approach, New Technology Group 7	N		
XW043C7	Introduction of Autologous Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7	N**	PRE	018
XW043E6	Introduction of Etesevimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6	N(1)
XW043F6	Introduction of Bamlanivimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6	N(1)
XW043G6	Introduction of REGN-COV2 Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6	N(1)
XW043G7	Introduction of Allogeneic Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7	N**	PRE	018
XW043H6	Introduction of Other New Technology Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6	N(1)
XW043H7	Introduction of Axicabtagene Ciloleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7	N**	PRE	018
XW043J7	Introduction of Tisagenlecleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7	N**	PRE	018
XW043K7	Introduction of Idecabtagene Vicleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7	N**	PRE	018
XW043L6	Introduction of CD24Fc Immunomodulator into Central Vein, Percutaneous Approach, New Technology Group 6	N(1)
XW043L7	Introduction of Lifileucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7	N**	PRE	018
XW043M7	Introduction of Brexucabtagene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7	N**	PRE	018
XW043N7	Introduction of Lisocabtagene Maraleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7	N**	PRE	018
XW0DXM6	Introduction of Baricitinib into Mouth and Pharynx, External Approach, New Technology Group 6	N(1)
XW0G7M6	Introduction of Baricitinib into Upper GI, Via Natural or Artificial Opening, New Technology Group 6	N(1)
XW0H7M6	Introduction of Baricitinib into Lower GI, Via Natural or Artificial Opening, New Technology Group 6	N(1)
XW0V0P7	Introduction of Antibiotic-eluting Bone Void Filler into Bones, Open Approach, New Technology Group 7	N		

	Notes:
	(**)-Non-OR procedure affects DRGs
	(1)-Implemented January 1, 2021
